Biotechnology
Price
$126.75
-0.98%Market Cap
$25.69B
Day High
$128.08
Day Low
$126.04
Incyte's Q2 FY2026 10-Q filing did not include XBRL income statement, balance sheet, cash flow, or ratio data, so this analysis is based solely on qualitative disclosures from the MD&A and Risk Factors sections, which highlight continued reliance on JAKAFI, pipeline advancement (INCA033989, tafasitamab, latarcibart), and the newly approved JAKAFI XR extended-release formulation.
Key risk: Heavy Dependence on JAKAFI/JAKAVI Revenue
Incyte states that JAKAFI product sales are expected to continue contributing a significant percentage of total revenues over the next several years, but sales are expected to begin declining upon patent exclusivity expiration in 2028. Any inability to maintain JAKAFI revenues could materially harm the business and force delays in other drug discovery and commercialization initiatives.
Other Biotechnology companies